Skip to main content

Table 1 Summary of inputs and data sources used

From: Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

Treatment Vaborem BAT Comments and sources
Efficacy
 Cure 59.4%. 26.7% TANGO II [15]
 Mortality at day 28 15.6% 33.3% TANGO II [15]
Probability of discharge
 At home 77.3% 77.3% TANGO II, Menarini data on file [15, 19]
 For long-term care 22.7% 22.7% TANGO II, Menarini data on file [15, 19]
Probability of complication
 Septic shock 3.1% 26.7% TANGO II, Menarini data on file [15, 19]
 Nephrotoxicity 3.1% 26.7% TANGO II, Menarini data on file [15, 19]
 RRT (inpatient) 25.0% 25.0% Italian medical expert opinion. Applied to patients with nephrotoxicity
 RRT (after discharge) 40.0% 40.0% Italian medical expert opinion. Applied to patients who have received RRT even during admission.
Mortality for all causes (after 28 days)– Without Chronic RRT
 Year 1 29.6% 29.6% Calculated considering:
• Patients’ characteristics from TANGO II (sex and age) [15]
• Italian mortality tables [20]
• Proportion of patients with low (1–2), medium (3–4) and high (≥5) CCI of 10.6, 10.6 and 78.7%, respectively (TANGO II) [15]
• HR as per CCI level [21]
 Year 2 30.3% 30.3%
 Year 3 31.0% 31.0%
 Year 4 31.8% 31.8%
 Year 5 32.6% 32.6%
Mortality for all causes (after 28 days)– With Chronic RRT
 Year 1 61.4% 61.4% Calculated considering:
• Patients’ characteristics from TANGO II (sex and age) [15]
• Italian mortality tables [20]
• Proportion of patients with low (1–2), medium (3–4) and high (≥5) CCI of 10.6, 10.6 and 78.7%, respectively (TANGO II) [15]
• Scottish register of RRT patients [22]
 Year 2 70.3% 70.3%
 Year 3 75.4% 75.4%
 Year 4 89.2% 89.2%
 Year 5 92.4% 92.4%
  1. BAT: Best Available Therapy; mCRE-MITT: microbiologic-CRE-modified intent-to-treat; RRT: Renal Replacement Therapy; HR: Hazard Ratio; CCI: Charlson Comorbidity Index